Litigation Update: FDA Denies Request to Add Birth Defect Warning to Zofran’s Label

Litigation Update: FDA Denies Request to Add Birth Defect Warning to Zofran’s Label The FDA has notified Novartis that it has rejected their request to add a birth defect warning to Zofran’s label. Plaintiffs claim that Zofran, a drug used to treat nausea for cancer and surgery patients, was also promoted by GlaxoSmithKline – the … Continue reading “Litigation Update: FDA Denies Request to Add Birth Defect Warning to Zofran’s Label”

Copyright ©2021 Medical Injury Help, ForLawFirmsOnly Marketing, Inc. All Rights Reserved